SVRA Stock Overview
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Savara Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.49 |
52 Week High | US$5.70 |
52 Week Low | US$3.12 |
Beta | 0.96 |
11 Month Change | 2.75% |
3 Month Change | 22.68% |
1 Year Change | 18.78% |
33 Year Change | 245.38% |
5 Year Change | 60.36% |
Change since IPO | -48.74% |
Recent News & Updates
Savara: Trial Successful, But I'm Only Half Convinced
Sep 09Savara: Today's Data 'Win' Rouses Market All Too Briefly
Jun 26Savara: The Binary Bet On Phase 3 Data
Jun 07Recent updates
Savara: Trial Successful, But I'm Only Half Convinced
Sep 09Savara: Today's Data 'Win' Rouses Market All Too Briefly
Jun 26Savara: The Binary Bet On Phase 3 Data
Jun 07Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?
Dec 14Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Feb 16Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Oct 12Savara's rare lung disorder drug gets promising innovative medicine status in UK
Aug 26Savara GAAP EPS of -$0.06 in-line
Aug 11Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?
Jan 24Is Savara (NASDAQ:SVRA) A Risky Investment?
Jul 05Savara: They Failed Once, But They Are Trying Again
Jun 07The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares
Mar 17Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares
Feb 26Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
Nov 24Savara EPS misses by $0.01
Nov 05Shareholder Returns
SVRA | US Biotechs | US Market | |
---|---|---|---|
7D | 6.9% | -1.2% | 1.6% |
1Y | 18.8% | 22.9% | 30.6% |
Return vs Industry: SVRA underperformed the US Biotechs industry which returned 22.5% over the past year.
Return vs Market: SVRA underperformed the US Market which returned 30.5% over the past year.
Price Volatility
SVRA volatility | |
---|---|
SVRA Average Weekly Movement | 8.7% |
Biotechs Industry Average Movement | 10.2% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SVRA has not had significant price volatility in the past 3 months.
Volatility Over Time: SVRA's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 37 | Matt Pauls | www.savarapharma.com |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
Savara Inc. Fundamentals Summary
SVRA fundamental statistics | |
---|---|
Market cap | US$739.06m |
Earnings (TTM) | -US$75.29m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.8x
P/E RatioIs SVRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SVRA income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$45.63m |
Gross Profit | -US$45.63m |
Other Expenses | US$29.66m |
Earnings | -US$75.29m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.46 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 26.0% |
How did SVRA perform over the long term?
See historical performance and comparison